Back to Treatments

Treatment

Nivolumab

3
Conditions
193
Trials
27K
Participants
38%
Average Safety

Condition Evidence

Brain and central nervous system cancer

41 trials · 8,000 participants

20% effectiveness · 40% safety

Malignant skin melanoma

48 trials · 11K participants

87% effectiveness · 35% safety

Stomach cancer

104 trials · 8,000 participants

60% effectiveness · 40% safety
Nivolumab | DFDA